Melanocortin peptide therapeutics: Historical milestones, clinical studies and commercialization

Mac E. Hadley; Robert T. Dorr

doi:10.1016/j.peptides.2005.01.029

Melanocortin peptide therapeutics: Historical milestones, clinical studies and commercialization

Mac E. Hadley, Robert T. Dorr

Cancer Center

Research output: Contribution to journal › Review article › peer-review

82 Scopus citations

Abstract

The melanocortins (MCs) are a family of multifunctional peptidergic hormones. Several superpotent, prolonged acting, enzymatically resistant, MC analogs have been designed and synthesized to help clarify the nature and role of MCs and their receptors (MCRs) in physiological functions. Two of these analogs, a linear peptide, melanotan I, and a cyclic truncated peptide, melanotan II (MTI and MTII, respectively) have been patented and tested clinically for studies on tanning of the skin (MTI) and for diagnosis and treatment of male erectile dysfunction (MTII). A new MTII analog, PT-141 (Palatin Technologies) has initial phase I/II trials and is scheduled to enter pivotal stage III clinical trials leading to commercialization. MTI may provide a therapeutic tan with the potential to lower the risk of skin cancer. PT-141 may improve sexual functionality in both males and females.

Original language	English (US)
Pages (from-to)	921-930
Number of pages	10
Journal	Peptides
Volume	27
Issue number	4
DOIs	https://doi.org/10.1016/j.peptides.2005.01.029
State	Published - Apr 2006

Keywords

Erectile dysfunction
Melanocortin
Melanocyte
Melanogenesis
Melanoma
POMC

ASJC Scopus subject areas

Biochemistry
Physiology
Endocrinology
Cellular and Molecular Neuroscience

Access to Document

10.1016/j.peptides.2005.01.029

Cite this

@article{d6f483b8f3524454b12cb0f04914b9c5,

title = "Melanocortin peptide therapeutics: Historical milestones, clinical studies and commercialization",

abstract = "The melanocortins (MCs) are a family of multifunctional peptidergic hormones. Several superpotent, prolonged acting, enzymatically resistant, MC analogs have been designed and synthesized to help clarify the nature and role of MCs and their receptors (MCRs) in physiological functions. Two of these analogs, a linear peptide, melanotan I, and a cyclic truncated peptide, melanotan II (MTI and MTII, respectively) have been patented and tested clinically for studies on tanning of the skin (MTI) and for diagnosis and treatment of male erectile dysfunction (MTII). A new MTII analog, PT-141 (Palatin Technologies) has initial phase I/II trials and is scheduled to enter pivotal stage III clinical trials leading to commercialization. MTI may provide a therapeutic tan with the potential to lower the risk of skin cancer. PT-141 may improve sexual functionality in both males and females.",

keywords = "Erectile dysfunction, Melanocortin, Melanocyte, Melanogenesis, Melanoma, POMC",

author = "Hadley, {Mac E.} and Dorr, {Robert T.}",

note = "Funding Information: This work was funded by numerous NIH grants early on and more recently by several pharmaceutical companies. We acknowledge the efforts of many students and other members of the “Arizona Team”. Both authors have and will probably continue to benefit financially from the commercialization of the technologies discussed above. Dr. Dorr is a consultant and shareholder of EpiTan Ltd. Drs. Hadley and Dorr have received royalties from Palatin and EpiTan Ltd. through Competitive Technologies agreement with the University of Arizona. ",

year = "2006",

month = apr,

doi = "10.1016/j.peptides.2005.01.029",

language = "English (US)",

volume = "27",

pages = "921--930",

journal = "Peptides",

issn = "0196-9781",

publisher = "Elsevier Inc.",

number = "4",

}

TY - JOUR

T1 - Melanocortin peptide therapeutics

T2 - Historical milestones, clinical studies and commercialization

AU - Hadley, Mac E.

AU - Dorr, Robert T.

N1 - Funding Information: This work was funded by numerous NIH grants early on and more recently by several pharmaceutical companies. We acknowledge the efforts of many students and other members of the “Arizona Team”. Both authors have and will probably continue to benefit financially from the commercialization of the technologies discussed above. Dr. Dorr is a consultant and shareholder of EpiTan Ltd. Drs. Hadley and Dorr have received royalties from Palatin and EpiTan Ltd. through Competitive Technologies agreement with the University of Arizona.

PY - 2006/4

Y1 - 2006/4

N2 - The melanocortins (MCs) are a family of multifunctional peptidergic hormones. Several superpotent, prolonged acting, enzymatically resistant, MC analogs have been designed and synthesized to help clarify the nature and role of MCs and their receptors (MCRs) in physiological functions. Two of these analogs, a linear peptide, melanotan I, and a cyclic truncated peptide, melanotan II (MTI and MTII, respectively) have been patented and tested clinically for studies on tanning of the skin (MTI) and for diagnosis and treatment of male erectile dysfunction (MTII). A new MTII analog, PT-141 (Palatin Technologies) has initial phase I/II trials and is scheduled to enter pivotal stage III clinical trials leading to commercialization. MTI may provide a therapeutic tan with the potential to lower the risk of skin cancer. PT-141 may improve sexual functionality in both males and females.

AB - The melanocortins (MCs) are a family of multifunctional peptidergic hormones. Several superpotent, prolonged acting, enzymatically resistant, MC analogs have been designed and synthesized to help clarify the nature and role of MCs and their receptors (MCRs) in physiological functions. Two of these analogs, a linear peptide, melanotan I, and a cyclic truncated peptide, melanotan II (MTI and MTII, respectively) have been patented and tested clinically for studies on tanning of the skin (MTI) and for diagnosis and treatment of male erectile dysfunction (MTII). A new MTII analog, PT-141 (Palatin Technologies) has initial phase I/II trials and is scheduled to enter pivotal stage III clinical trials leading to commercialization. MTI may provide a therapeutic tan with the potential to lower the risk of skin cancer. PT-141 may improve sexual functionality in both males and females.

KW - Erectile dysfunction

KW - Melanocortin

KW - Melanocyte

KW - Melanogenesis

KW - Melanoma

KW - POMC

UR - http://www.scopus.com/inward/record.url?scp=33645407840&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645407840&partnerID=8YFLogxK

U2 - 10.1016/j.peptides.2005.01.029

DO - 10.1016/j.peptides.2005.01.029

M3 - Review article

C2 - 16412534

AN - SCOPUS:33645407840

SN - 0196-9781

VL - 27

SP - 921

EP - 930

JO - Peptides

JF - Peptides

IS - 4

ER -

Melanocortin peptide therapeutics: Historical milestones, clinical studies and commercialization

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this